ARTICLE | Emerging Company Profile

Gene editing vets launch Korro to convert RNA bases

Atlas, NEA launch Korro with new take on RNA base editing, trio of gene editing veterans

October 7, 2019 10:01 AM UTC
Updated on Oct 7, 2019 at 6:35 PM UTC

A trio of gene editing industry veterans have teamed up to launch Korro Bio as their second company developing antisense-based therapies in less than a year. Korro is creating a new CRISPR-independent version of RNA base editing that pairs antisense technology with an endogenous RNA-modifying enzyme to precisely swap single target bases.

The company launched on Monday with undisclosed funding from Atlas Venture and NEA, and a team led by co-founders Nessan Bermingham, Andrew Fraley and Jean-François Formela, who also co-founded Triplet Therapeutics Inc. last year. ...